FDA pulls authorization for AstraZeneca COVID treatment, says it's ineffective against some variants
Medicine "not expected to provide protection against developing COVID-19."
The Facts Inside Our Reporter’s Notebook
The U.S. Food and Drug Administration this week pulled its emergency use authorization of a COVID-19 treatment, claiming multiple variants of the virus that causes the disease are rendering it ineffective.
The FDA said in a Friday press release that AstraZeneca's Evusheld preventative medicine "is not expected to provide protection against developing COVID-19" if patients are exposed to certain variants of SARS-CoV-2.
The variants in question "are projected to be responsible for more than 90% of current infections in the U.S.," the FDA said. The revocation of the use authorization will be maintained "until further notice by the Agency."
The agency had already warned earlier this month that the treatment was likely increasingly ineffective against new forms of SARS-CoV-2.
Just News, No Noise
- Congress probing if FBI used ‘Russian disinformation’ claim to shut down Biden inquiries
- Lawmaker probing J6 security failures: 'People of interest’ may have withheld critical intel
- Doctored evidence? Democrat-led J6 panel added audio to silent security video for primetime hearings
- Texas governor says he wants to eliminate property taxes
- Biden sanctions Iran tech firm for censorship while remaining silent on censoring US citizens